Valuable Serum Markers in Pulmonary Alveolar Proteinosis

Abstract EN

Objective.

Several serum markers were reported to reflect the severity of pulmonary alveolar proteinosis (PAP).

The aim of this study is to investigate a reliable and facile marker to access and monitor the clinical course of PAP in a large cohort.

Methods.

PAP patients from January 2010 to June 2018 were enrolled.

Hospital records were used as data sources.

The levels of various serum indicators were detected.

We evaluated the correlation between pulmonary function test results and clinical variables.

Results.

Diffusion capacity for carbon monoxide (DLCO) level was positively correlated with the level of high-density lipoprotein cholesterol (HDL-C) (P<0.05) in 122 patients of PAP at baseline.

The levels of HDL-C and DLCO significantly increased while carcinoembryonic antigen (CEA), CYFRA21-1, neuron-specific enolase (NSE), and lactic dehydrogenase (LDH) levels decreased six months after granulocyte-macrophage colony-stimulating factor (GM-CSF) inhalation therapy between 14 patients with PAP.

Nevertheless, the increased DLCO was significantly correlated with decreased CEA (r=‐0.579, P=0.031) and CYFRA 21-1 (r=‐0.632, P=0.015).

In 10 PAP patients without GM-CSF inhalation therapy, HDL-C and DLCO significantly decreased while NSE and LDH levels increased after six months of follow-up.

The decreased DLCO was significantly correlated with increased LDH (r=‐0.694, P=0.026).

Conclusions.

Serum CEA, CYFRA21-1, and LDH are valuable serum markers for the evaluation of disease activity of PAP and may predict the response to treatment of PAP.